Novo Nordisk A/S Common Stock (NY:NVO)

As of late February 2026, the financial narrative of the past two years has been dominated by a singular force in the healthcare sector: Eli Lilly & Company (NYSE: LLY). Once considered a traditional...

The Lilly Era: How Eli Lilly Transformed into a Trillion-Dollar Healthcare Titan

Today 11:55 EST

As of February 27, 2026, the narrative surrounding Novo Nordisk (NYSE: NVO) has undergone a dramatic transformation. For the better part of three years, the Danish pharmaceutical giant was the...

Topics Artificial Intelligence ETFs

The Valuation Reset: A Deep-Dive into Novo Nordisk (NVO) in 2026

Today 10:18 EST

Via Finterra

Topics Economy Intellectual Property

Got $5,000? Hims & Hers Could Be a Direct‑to‑Consumer Health Moonshot in the Making ↗

Today 5:08 EST

Hims & Hers is facing some well-deserved pushback from Novo Nordisk, but the big picture is still promising.

The maker of Wegovy hasn't said its last words just yet.

Forget Altimmune: This Proven Obesity‑Drug Giant Is the Better Weight‑Loss Play ↗

February 26, 2026

The weight-loss drug innovator is falling behind in the industry and facing major pricing pressures.

Why Shares of Novo Nordisk Stock Sank (Again) This Week ↗

February 26, 2026

The Darwinian Transition: AI Monetization and Metabolic Mastery Define the Market’s New Frontier

Viking Therapeutics: The High-Stakes Weight Loss Contender ↗

February 26, 2026

Via MarketBeat

February 26, 2026

As the final week of February 2026 draws to a close, the financial markets have emerged from what analysts are calling the most consequential “Heavyweight Week” of the post-pandemic era. The...

As of February 26, 2026, Hims & Hers Health, Inc. (NYSE: HIMS) finds itself at the center of one of the most polarized debates in the modern healthcare sector. Once the "poster child" of the 2024-2025...

Topics Artificial Intelligence Economy

Hims & Hers at the Crossroads: Navigating the ‘Regulatory Winter’ of 2026

February 26, 2026

Via Finterra

Topics Economy Initial Public Offering Intellectual Property

Hims & Hers: The Telehealth Growth Story Younger Investors Can't Afford to Ignore ↗

February 26, 2026

How fast can Hims & Hers grow without selling GLP-1 drugs? Maybe a lot faster than you think.

Stock Market Today, Feb. 25: Novo Nordisk Dips After Announcing $2.1 Billion Partnership With Vivtex for Oral Drug-Delivery Technologies ↗

February 25, 2026

Investors weigh steep GLP‑1 price cuts against a multibillion‑dollar oral obesity push, fresh analyst caution, and a new partnership, today, Feb. 25, 2026.

Eli Lilly Just Took 2 Major Steps Forward in the Billion-Dollar Obesity Drug Market. Here's What You Need to Know. ↗

Topics Stocks

February 25, 2026

Eli Lilly has seen revenue and earnings soar in recent years.

Although pegged as a weight-loss stock, this drug maker's core business has long been diabetes.

1 Reason Why I'd Hold This Weight‑Loss Drug Leader Through Any Market Crash ↗

February 25, 2026

Novo, Vivtex Ink $2.1 Billion Deal To Develop Oral Medicines For Obesity And Diabetes ↗

Topics Economy

February 25, 2026

Novo Nordisk will lead global development, regulatory approval, manufacturing, and commercialization of the resulting products.

Novo Nordisk (NYSE: NVO) announced plans to cut the list prices of these drugs by up to 50% in the U.S. starting in 2027, on Tuesday.

Novo Nordisk To Slash GLP-1 Drug Prices By Up To 50% In US Starting 2027 ↗

February 25, 2026

Via Benzinga

Could Novo Nordisk Help Turn $100,000 Into $1 Million in the GLP‑1 Gold Rush? ↗

February 25, 2026

It would be a near-miracle gain.

Investors worried that the company could take quite a revenue hit due to a competitor's move.

Why Eli Lilly Stock Slumped Today ↗

February 24, 2026

Shares of Novo Nordisk and Eli Lilly slipped in afternoon trade after the former announced a reduction in the list prices of its weight loss drugs, Ozempic and Wegovy.

Novo's 'Flashy' Ozempic, Wegovy Price Cuts Unlikely To Impact LLY Stock, Says BofA ↗

February 24, 2026

According to a report by The Wall Street Journal, Ozempic and Wegovy prices will start at a list price of $675 a month, effective Jan. 1, 2027.

Novo Nordisk To Cut Ozempic, Wegovy Prices By Up To 50%: Report ↗

February 24, 2026

NVO Stock Continues To Decline Pre-Market After Monday’s Crash Amid CagriSema Setback – But Tuesday Brings Some Hope From China ↗

Topics Artificial Intelligence

February 24, 2026

Developed in partnership with United Laboratories International Holdings, Novo Nordisk said that UBT251 delivered up to 19.7% mean weight loss after 24 weeks in a phase 2 trial in China.

Got $5,000? Viking Therapeutics Might Be a Weight‑Loss Drug Moon Shot in the Making. ↗

February 23, 2026

Is this the best way to cash in on the weight-loss gold rush?

Today, Feb. 23, 2026, a pivotal obesity‑drug trial setback forces investors to rethink Novo Nordisk’s strategy.

Stock Market Today, Feb. 23: Novo Nordisk Plunges 16% After Obesity Drug Falls Short ↗

February 23, 2026

Stock Market Today, Feb. 23: Nvidia Earnings Loom as Tariff Concerns Drive Dow 800 Points Lower ↗

Topics Stocks

February 23, 2026

AI jitters, tariff shock, and looming Nvidia results have investors fleeing growth for perceived safety, today, Feb. 23, 2026.

Novo Nordisk Shares Tumble 15.1% After CagriSema Fails to Topple Eli Lilly in Head-to-Head Trial

Topics Artificial Intelligence Government Stocks

February 23, 2026

The undisputed reign of Novo Nordisk in the weight-loss drug sector faced its most severe challenge to date on February 23, 2026, as the company’s US-traded shares (NYSE: NVO) plummeted 15.1% in a...

Check out the stocks that are attracting the most attention and driving market activity. ↗

February 23, 2026

Via Chartmill

Why Viking Therapeutics Stock Is Up More Than 9% Today ↗

February 23, 2026

A potential competitive threat to Viking's phase 3 weight-loss drug VK2735 was just dealt a major blow.

Eli Lilly has some good news for investors today. Novo Nordisk has some bad news (which is also good news for Lilly).

Why Eli Lilly Stock Just Popped ↗

February 23, 2026

GLP-1 weight loss drug CagriSema may not be the salvation Novo Nordisk was hoping for.

Why Novo Nordisk Stock Just Crashed ↗

February 23, 2026

High Volatility and Earnings Crossroads: A Deep Dive into Hims & Hers Health (HIMS) in 2026

February 23, 2026

As of February 23, 2026, Hims & Hers Health, Inc. (NYSE: HIMS) finds itself at a critical crossroads that has sent shockwaves through the telehealth and pharmaceutical sectors. Once the darling of the...

Via Finterra

Topics Artificial Intelligence Intellectual Property Lawsuit

Eli Lilly Surges as Novo Nordisk’s "CagriSema" Stumbles in High-Stakes Obesity Head-to-Head

February 23, 2026

Shares of Eli Lilly (NYSE: LLY) climbed 3.5% on February 23, 2026, as the pharmaceutical giant tightened its grip on the multi-billion-dollar obesity market. The rally was fueled by disappointing...